London, UK – June 4th, 2018 – NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis has been granted the Innovative Business of the Year award at the Business Eye First Trust Awards (BEFTAs), an award for small businesses in Northern Ireland. The award, issued by First Trust Bank, saw ProAxsis emerge the elected winner amongst a group of companies from diverse sectors.
Commenting on the news, NetScientific’s Chief Executive Officer and Chairman of ProAxsis, Francois R. Martelet said: “We are extremely pleased with this outcome and want to extend our congratulations to the ProAxsis team for the ongoing hard work and dedication. It is splendid to see their efforts materialising and gaining recognition, and we look forward to their continued progress for what has been a fantastic year for them thus far.”
NetScientific holds 54% of ProAxsis on a fully-diluted basis.
The full text of the announcement from ProAxsis can be found below.
# # #
For more information, please contact:
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
|Tel: +44 (0)20 3514 1800|
Consilium Strategic Communications
Mary-Jane Elliott Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
|Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
|Tel: +44 (0) 20 7710 7600|
ProAxsis wins Innovative Business of the Year Award
Date: June 4th 2018
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland.
The glittering awards ceremony took place on the evening of Thursday May 31st at the Crowne Plaza Hotel in Belfast, and was compered by the UTV newsreader and Northern Ireland correspondent for ITV, Marc Mallett. Over 400 people were in attendance, with more than 50 Northern Irish businesses shortlisted across the 14 award categories.
The ProAxsis team were announced as the Innovative Business of the Year by Tina McKenzie, the Chair of the Federation of Small Businesses NI, who sponsored the innovation category.
Dr David Ribeiro, CEO of ProAxsis, commented: “This is fabulous recognition for the whole team at ProAxsis, who work incredibly hard in order to maximise the potential of our novel ProteaseTag® technology. We’re thrilled to have won our first BEFTA, in what was described as one of the most competitive categories of the event, and would like to thank the organisers, Business Eye, as well as the judging panel and the sponsors for the event.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact email@example.com
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. Its first commercialised immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.